[{"Assets_0_Q3_USD":420118000.0,"CommonStockSharesOutstanding_0_Q3_shares":39179019.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-85115000.0,"NetIncomeLoss_1_Q3_USD":-37703000.0,"NetIncomeLoss_3_Q3_USD":-99092000.0,"StockholdersEquity_0_Q3_USD":341240000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":39130101.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":37053202.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":39130101.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":37053202.0,"Ticker":"BPMC","CIK":"1597264","name":"BLUEPRINT MEDICINES CORP","OfficialName":"Blueprint Medicines Corporation Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"3980842399.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171031"}]